CTLA4 and cancer: Our data presented herein not only establish a fundamental converging pathway to improve safety and to enhance efficacy of anti-CTLA-4 antibodies, but also demonstrate how this new pathway can be explored to convert an irAE-prone and ineffective anti-CTLA-4 antibody into a safer and more effective one to meet the unmet medical needs in cancer immunotherapy.